HIV Lipodystrophy
11
0
0
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
90.0%
+3.5% vs benchmark
27%
3 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals
The Visceral Adiposity Measurement and Observation Study
Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults
Effects of Growth Hormone Releasing Hormone in HIV
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
Effects of IGF-I in HIV Metabolic Disease
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
Effects of Short-term Growth Hormone in HIV-infected Patients
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
Yoga for the Management of HIV-Metabolic Syndromes